STOCK TITAN

Adage group reports 5.82% Relmada Therapeutics (RLMD) ownership stake

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Relmada Therapeutics, Inc. is the subject of a Schedule 13G showing that Adage Capital Management, L.P. and related individuals beneficially own 4,270,000 shares of its common stock, representing 5.82% of the class. This percentage is based on 73,333,622 shares outstanding as of November 10, 2025.

The reporting persons have shared voting and dispositive power over all reported shares and no sole power. They state the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Relmada Therapeutics.

Positive

  • None.

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does the Relmada Therapeutics (RLMD) Schedule 13G filing disclose?

The filing discloses that Adage Capital Management and affiliates beneficially own 4,270,000 Relmada Therapeutics shares, or 5.82% of the common stock, based on 73,333,622 shares outstanding. It is a passive ownership report, not a control-seeking filing.

How many Relmada Therapeutics (RLMD) shares does Adage beneficially own?

Adage Capital Management and related reporting persons beneficially own 4,270,000 shares of Relmada Therapeutics common stock. This stake represents 5.82% of the company’s outstanding common stock, calculated using 73,333,622 shares outstanding as of November 10, 2025.

What percentage of Relmada Therapeutics (RLMD) does Adage’s 13G stake represent?

The reported position equals 5.82% of Relmada Therapeutics’ common stock. That percentage is calculated using 73,333,622 shares outstanding as of November 10, 2025, as disclosed in the company’s Form 10-Q for the quarter ended September 30, 2025.

Do the Adage reporting persons have voting control over their Relmada (RLMD) shares?

The reporting persons have shared voting and shared dispositive power over 4,270,000 Relmada shares, with no sole voting or dispositive power. This means voting and decisions to sell the shares are controlled jointly rather than individually by any one reporting person.

Is Adage seeking to influence control of Relmada Therapeutics (RLMD)?

The filers certify the Relmada Therapeutics shares were acquired and are held in the ordinary course of business. They explicitly state the holdings are not for the purpose of changing or influencing control of the issuer or participating in a control-related transaction.

Who are the reporting persons in the Relmada Therapeutics (RLMD) Schedule 13G?

The reporting persons are Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross. Adage acts as investment manager to Adage Capital Partners, L.P., which directly holds the Relmada shares, while Atchinson and Gross are managing members of related general partner entities.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Adage Capital Management, L.P.
Signature:/s/ Robert Atchinson
Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
Date:02/12/2026
Robert Atchinson
Signature:/s/ Robert Atchinson
Name/Title:Robert Atchinson, individually
Date:02/12/2026
Phillip Gross
Signature:/s/ Phillip Gross
Name/Title:Phillip Gross, individually
Date:02/12/2026
Exhibit Information

Exhibit 99.1: Joint Filing Agreement